| Oct 15 |
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
|
| Oct 8 |
InspireMD Advances with FDA Study Approval and Global Goals
|
| Oct 7 |
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
|
| Sep 16 |
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
|
| Sep 14 |
Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 88% over the last five years
|
| Aug 9 |
InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
Companies Like InspireMD (NASDAQ:NSPR) Are In A Position To Invest In Growth
|
| Aug 6 |
InspireMD GAAP EPS of -$0.22, revenue of $1.74M
|
| Aug 6 |
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 5 |
InspireMD Q2 2024 Earnings Preview
|
